Kira Pharmaceuticals Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

Cambridge MA US

Primary Industry

Biotechnology

About

Based in Massachusetts, US, and found in 2017, Kira Pharmaceuticals Ltd. operates as a biotechnology company that develops antibody drugs and immune antibody therapy for the treatment of immune and oncological disorders and diseases. With the company's LOGIC drug discovery platform, it enables medical staff to complement mediation in new and different ways, unlocking transformative therapies for patients. The company is headquartered in Cambridge, Massachusetts with an R&D center in Suzhou, China. In January 2021, received an oversubscribed USD 53.5 million Series B+ financing co-led by RA Capital Management and Vivo Capital. Kira Pharmaceuticals focuses on therapeutic inflammatory and autoimmune diseases and oncology. The company's most advanced program, P014, is a biologic molecule designed to inhibit both upstream and downstream complement targets by regulating two separate rate-limiting steps in the complement activation cascade critical for disease development. With the series B investment received, Kira Pharmaceuticals continue to advance its lead asset P014, a bifunctional biologic entering the clinic soon, and a pipeline of important complement-targeted therapies for patients in need.

Current Investors

Qiming Venture Partners, Sinopharm Capital, 6 Dimensions Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.kirapharma.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.